Selection from HEOR Bibliography
| Search criteria | ||||
| Norway |
||||
| Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study | ||||
| Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group | ||||
| "1 Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel 2 Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany 3 German Centre for Diabetes Research (DZD), München-Neuherberg, Germany 4 Department of Health Service Administration, China Medical University, Taichung, Taiwan 5 Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan 6 Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan 7 Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan 8 Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan 9 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea 10 Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan 11 Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK 12 Institute of Applied Health Research, University of Birmingham, Birmingham, UK 13 Midlands Health Data Research UK, Birmingham, UK 14 DEMAND Hub, University of Birmingham, Birmingham, UK 15 Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden 16 Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland 17 IQVIA Solutions Denmark A/S, Copenhagen, Denmark 18 IQVIA, Espoo, Finland 19 IQVIA, Tartu, Estonia 20 Boehringer Ingelheim International GmbH, Ingelheim, Germany 21 Boehringer Ingelheim International GmbH, US 22 Lilly Deutschland GmbH, Bad Homburg, Germany 23 Steno Diabetes Center Copenhagen, Herlev, Denmark 24 Department of Public Health, University of Copenhagen, Copenhagen, Denmark 25 Department of Cardiology, Oslo University Hospital UllevÃ¥l, and University of Oslo, Oslo, Norway 26 Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway 27 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA 28 Department of Cardiology, Hospital ClÃnico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain" | ||||
| "Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636 Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October" |
||||
| , Article | ||||
| , Denmark, Finland, Germany, Norway, Spain, Sweden, UK | ||||
| Abstract: https://doi.org/10.1016/j.diabet.2022.101418 (https://www.sciencedirect.com/science/article/pii/S1262363622000994) | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study | 2023 | English | , Clinical setting: hospital, Clinical setting: Primary care | |
| The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis | ||||
| Helmut Butzkueven, Jan Hillert, Merja Soilu-Hänninen, Tjalf Ziemssen, Jens Kuhle, Stig Wergeland, Melinda Magyari, Joseph R. Berger, Nicholas Moore, Aida Aydemir, Irene Bezemer & Meritxell Sabidó | ||||
| "a Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia; b The Alfred Hospital, Melbourne, VIC, Australia; c Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; d Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland; e Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany; f Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland; g Department of Neurology, University Hospital and University of Basel, Basel, Switzerland; h Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway; i Department of Clinical Medicine, University of Bergen, Bergen, Norway; j Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; k Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; l Bordeaux PharmacoEpi (BPE), Universit�e de Bordeaux, Bordeaux, France; m EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA; n Global Epidemiology, IQVIA, Amsterdam, The Netherlands; o Merck Healthcare KGaA, Darmstadt, Germany" | ||||
| , Article | ||||
| , Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey | ||||
| Abstract: https://www.tandfonline.com/doi/full/10.1080/03007995.2023.2256220 | ||||
| Condition | Year | Language | Analysis type | |
| , Comparative Effectiveness & Health Technology Assessment, Drug safety, Neurological disorders | 2023 | English | , clinical setting: Secondary care, Epidemiological study, Population Based Study | |
| The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets | ||||
| Helmut Butzkueven 1 2, Nicholas Moore 3, Aida Aydemir 4, Jaak Sõnajalg 5, Irene Bezemer 6, Pasi Korhonen 7, Meritxell Sabidó 8, CLARION Study Group | ||||
| 1Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia. 2The Alfred Hospital, Melbourne, Australia. 3Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France. 4Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA). 5Global Database Studies, IQVIA, Tartu, Estonia. 6Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands. 7IQVIA (former EPID Research), Espoo, Finland. 8Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany. | ||||
| Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2059977 |
||||
| , Article | ||||
| , Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/35357268/ | ||||
| Condition | Year | Language | Analysis type | |
| , Drug safety, Neurological disorders | 2022 | English | , clinical setting: Secondary care, Epidemiological study, Observational study, Population Based Study, Retrospective database analysis | |
| A Survey Among Health Care Professionals to Assess Their Knowledge and Understanding on Darzalex® (Daratumumab) Educational Materials Regarding the Risk of Interference for Blood Typing in 12 European Countries | ||||
| Mathieu Rosé, Intissar Bourahla, Alessandro Ghiddi, Assem Al-Akabawi, Edmond Chan, Massoud Toussi | ||||
| IQVIA, Courbevoie, France; Janssen EMEA, Medical Affairs, Italy; Janssen EMEA, Medical Affairs, UK | ||||
| Presented at ISPE’s 35th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE 2019), August 24–28, 2019 at the Pennsylvania Convention Center, Philadelphia, PA, USA. |
||||
| , Poster | ||||
| , Austria, Czech, Denmark, Finland, France, Germany, Hungary, Norway, Slovakia, Spain, Sweden, Switzerland | ||||
| Abstract: https://www.coodoc.com/pages/p1822-Daratumumab-ICPE-2019 | ||||
| Condition | Year | Language | Analysis type | |
| , Hematology, Oncology | 2019 | English | , Public Health, Survey research | |
| No increased risk of spontaneous abortion and ectopic pregnancy after exposure to interferon-beta prior to or during pregnancy: Results from register-based Nordic study among women with MS | ||||
| R. Juuti1, K. M. Hakkarainen 1, S. Burkill 2, Y. Geissbuehler 3, M. Sabidó 4, C. Popescu 5, A. Adamo 6, J. Hillert 2, S. Cnattingius 2, M. Artama 7, A. Verkkoniemi-Ahola 8, K.-M. Myhr 9, J. Mehtälä 1, S. Bahmanyar 2, S. Montgomery 2,10, P. Korhonen 1 and the European Interferon Beta Pregnancy Study Group | ||||
| 1StatFinn-EPID Research, Espoo, Finland | ||||
| EAN, Oslo, Norway, June 29-2 July, 2019 |
||||
| , Oral presentation | ||||
| , Finland, Germany, Norway, Sweden, Switzerland, UK | ||||
| Abstract: https://www.ean.org/fileadmin/_files/AbstractBook/EAN_Journal_2019_Book.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Neurological disorders | 2019 | English | , Epidemiological study, Population Based Study, Retrospective database analysis | |
| Assessing the Outcomes for Orphan Status or Accelerated Assessment EMA Approved Medicines: A Comparison of Health Technology Assessment in Denmark, Finland, Norway and Sweden | ||||
| Falla, Edel; Pitcher, Ashley; Acs, Annabel; Heller, Vincent; Zhang, Rongrong | ||||
| IQVIA, Real-World Insights, London, LON, UK IQVIA, Real-World Insights, Copenhagen, Denmark IQVIA, Real-World Insights, Copenhagen, Denmark IQVIA, Real-World Insights, Solna, AB, Sweden IQVIA, Real-World Insights, Stockholm, Sweden | ||||
| ISPOR Europe 2019, November 5, 2019, Copenhagen, Denmark |
||||
| , Poster | ||||
| , Denmark, Finland, Nordic, Norway, Sweden | ||||
| Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(19)34089-6/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301519340896%3Fshowall%3Dtrue#%20 | ||||
| Condition | Year | Language | Analysis type | |
| , Comparative Effectiveness & Health Technology Assessment | 2019 | English | , Review | |
| Patient and caregiver indirect costs after acute cardiovascular events in Europe. | ||||
| Sidelnikov E1, Gerlier L2, Kutikova L1, Amarenco P3, Kotseva K4, Annemans L5 | ||||
| 1 Amgen (Europe) GmbH, Zug, Switzerland 2 IQVIA, Zaventem, Belgium 3 Paris-Diderot-Sorbonne University, Paris, France 4 National Heart & Lung Institute, Imperial College London, London, UK 5 Ghent University, Ghent, Belgium | ||||
| ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain |
||||
| , Oral presentation | ||||
| , Austria, Bulgaria, Croatia, Czech, Denmark, Finland, Germany, Greece, Italy, Norway, Romania, Slovakia, Slovenia | ||||
| Abstract: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/84816?pdfid=58963 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Health economics | 2018 | English | , Burden of illness, Cost of illness | |
| Feasibility Assessment for Conducting a Multi-Country Post-Marketing Safety Oncology Study Using Secondary Data Sources in Europe | ||||
| Wells KE, Jiang R, Tyczynski JE, Secrest M, Oliveria SA | ||||
| Wells KE: IQVIA; Jiang R: Abbvie; Tyczynski JE: Abbvie; Secrest M: IQVIA; Oliveria SA: IQVIA | ||||
| 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management |
||||
| , Abstract | ||||
| , Denmark, Finland, Germany, Norway, Sweden, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Database Validity and methodology, Oncology, Patient Registries & Real-World Study Methods | 2018 | English | , Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis, Review | |
| Different patterns of second?line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study | ||||
| Persson F, Bodegard J, Lahtela JT, Nyström T, Jørgensen ME, Jensen ML, Gulseth HL, Thuresson M, Hoti F, Nathanson D, Norhammar A, Birkeland KI, Eriksson JG, Eriksson JW | ||||
| StatFinn & EPID Research, Espoo, Finland | ||||
| Endocrinol Diabetes Metab. |
||||
| , Article | ||||
| , Denmark, Finland, Nordic, Norway, Sweden | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354817/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | , Population Based Study, Retrospective database analysis | |
| Predictors of Overall Survival for Multiple Myeloma Patients Depending on Transplant Status According to a Retrospective, Non-Interventional Study in Norway | ||||
| Fredrik H. Schjesvold, MD PhD, Anderson Jenna, Jaak Sõnajalg, Amy Leval, PhD, Anna Lysén, MSc, Saeeda Rana, Päivi Castren-Kortekangas, Fredrik Borgsten | ||||
| Fredrik H. Schjesvold - Oslo University; Jenna Anderson - EPID Research (now part of IQVIA); Jaak Sõnajalg - EPID Research (now part of IQVIA). | ||||
| Blood (2018) 132 (Supplement 1): 5759. |
||||
| , Abstract | ||||
| , Norway | ||||
| Abstract: https://ashpublications.org/blood/article/132/Supplement%201/5759/263137/Predictors-of-Overall-Survival-for-Multiple | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2018 | English | , Observational study, Population Based Study | |
| COMMONALITIES AND DIFFERENCES IN DATA COLLECTION ACROSS EUROPEAN SPONDYLOARTHRITIS REGISTRIES | ||||
| M. L. Hetland* 1, M. Østergaard1, J. Askling2, C. Gabay3, D. Nordstrom4, O. FitzGerald5, M. Hernández Miguel6, M. Santos7 , Z. Rotar8, H. Mann9, F. Iannone10, M. J. Nissen3, E. Hauge1, J. Gomez-Reino11, F. DÃaz-González12, M. Tomsic8, K. Pavelka9, F. O'Shea5, C. Sullivan5, M. van de Sande13, I. E. van der Horst-Bruinsma13, G. J. Macfarlane14, G. T. Jones14, B. Gudbjørnsson15, T. K. Kvien16 on behalf of EuroSpA Study Group | ||||
| 1DANBIO, Glostrup, Denmark, 2ARTIS, Stockholm, Sweden, 3SCQM, Geneva, Switzerland, 4ROB-FIN, Helsinki, Finland, 5ASRI, Dublin, Ireland, 6BIOBADASER, Barcelona, Spain, 7reuma.pt, Almada, Portugal, 8biorx.si, Ljubljana, Slovenia, 9ATTRA, Prague, Czech Republic, 10GISEA, Bari, Italy, 11BIOBADASER, Santiago, 12BIOBADASER, Santa Cruz de Tenerife, Spain, 13ARC, Amsterdam, Netherlands, 14BSRBR-AS, Aberdeen, United Kingdom, 15ICEBIO, Reykjavik, Iceland, 16NORDMARD, Oslo, Norway | ||||
| EULAR, Madrid, 2017 |
||||
| , Abstract | ||||
| , Czech, Denmark, Finland, Ireland, Italy, Norway, Slovenia, Spain, Sweden, Switzerland | ||||
| Abstract: http://ard.bmj.com/content/76/Suppl_2/656.3 | ||||
| Condition | Year | Language | Analysis type | |
| , Rheumatology | 2017 | English | , Epidemiological study | |
| Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. | ||||
| Svedman FC1, Pillas D2, Taylor A2, Kaur M2, Linder R3, Hansson J1. | ||||
| 1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden. 2Centre for Observational Research, Amgen Ltd, Uxbridge, UK. 3IMS Health Sweden, Stockholm, Sweden. | ||||
| Clinical Epidemiology |
||||
| , Article | ||||
| , Australia, Austria, Belgium, Bulgaria, Croatia, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Abstract: http://www-ncbi-nlm-nih-gov.proxy.kib.ki.se/pmc/articles/PMC4887072/ | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2016 | English | , Literature Review | |
| Use of Contraindicated Drugs in Pediatric Outpatients in the Nordic Countries | ||||
| Prami T, Långström D, Iso-Mustajärvi I, Sandler N | ||||
| EPID Research, Espoo, Finland | ||||
| Pharmacoepidemiology and Drug Safety (2016):25 (S3): pp. 3-679 |
||||
| , Abstract | ||||
| , Denmark, Finland, Norway, Sweden | ||||
| Abstract: https://onlinelibrary.wiley.com/doi/full/10.1002/pds.4070 | ||||
| Condition | Year | Language | Analysis type | |
| , Pediatrics | 2016 | English | , Retrospective database analysis | |
| Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. | ||||
| Emery P1, Gottenberg JE2, Rubbert-Roth A3, Sarzi-Puttini P4, Choquette D5, Taboada VM6, Barile-Fabris L7, Moots RJ8, Ostor A9, Andrianakos A10, Gemmen E11, Mpofu C12, Chung C13, Gylvin LH12, Finckh A14. | ||||
| 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK. 2Department of Rheumatology, CHU Strasbourg, Strasbourg, France. 3University of Cologne, Cologne, Germany. 4L Sacco University Hospital, Milan, Italy. 5University of Montreal, Montreal, Canada. 6Facultad de Medicina, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain. 7Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México City, Mexico. 8Department of Rheumatology, University of Liverpool, Liverpool, UK. 9Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. 10Hellenic Foundation for Rheumatological Research, Athens, Greece. 11Quintiles, Rockville, Maryland, USA. 12F Hoffmann-La Roche Ltd, Basel, Switzerland. 13Genentech Inc, San Francisco, California, USA. 14University Hospital of Geneva, Geneva, Switzerland. | ||||
| Ann Rheum Dis. 2015 Jun;74(6):979-84 |
||||
| , Article | ||||
| , Canada, Colombia, France, Germany, Greece, Italy, Mexico, Norway, Portugal, Spain, UK | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431330/ | ||||
| Condition | Year | Language | Analysis type | |
| , Comparative Effectiveness & Health Technology Assessment, Rheumatology | 2015 | English | , Clinical setting: hospital, clinical setting: Secondary care, Prospective study, RWLPR (Real-World Late Phase Research-quintiles | |
| Health economic evaluation of canagliflozin in the treatment of type 2 diabetes mellitus in Norway | ||||
| Troelsgaard A1, Huetson P2, Kjellberg J3, Hemels M1, Knudsen M4 | ||||
| Janssen A/S, Birkerød, Denmark, 2IMS Health, Stockholm, Sweden, 3Zefferin Farma AB, Stockholm, Sweden, 4IMS Health, Hellerup, Denmark | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , Nordic, Norway | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Economic evaluation | |
| Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. | ||||
| Jose´ R. Banegas 1,2*, Esther Lo´pez-Garcı´a 1,2, Jean Dallongeville3, Eliseo Guallar 4,5,6,7, Julian P. Halcox8, Claudio Borghi 9, Elvira L. Masso´-Gonza´lez 10, Francisco J. Jime´nez 11, Joep Perk12, Philippe Gabriel Steg13, Guy De Backer 14,and Fernando Rodrı´guez-Artalejo1,2 | ||||
| 1 Department of Preventive Medicine and Public Health, School of Medicine, Universidad Auto´noma de Madrid/IdiPAZ, Avda Arzobispo Morcillo, 2, 28029 Madrid, Spain; 2 CIBER of Epidemiology and Public Health, Madrid, Spain; 3 Inserm U 744, Institut Pasteur de Lille, 59019 Lille Cedex, France; 4 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 5 Department of Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 6 Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 7 Department of Cardiovascular Epidemiology and Population Genetics, National Center for Cardiovascular Research (CNIC), Madrid 28029, Spain; 8 Wales Heart Research Institute, Cardiff University, Heath Park, Cardiff CF14 4XN, UK; 9 Department of Internal Medicine, Aging and Clinical Nephrology, University of Bologna, Bologna, Italy; 10Medical Department, AstraZeneca Farmace´utica Spain, S.A., 28003 Madrid, Spain; 11Medical Department, AstraZeneca Europe, 1935 Zaventem, Belgium; 12School of Health and Caring Sciences, Linnaeus University, 391 82 Kalmar, Sweden; 13INSERM U 698, Assistance Publique–Hoˆpitaux de Paris and Universite´ Paris-Diderot, Paris, France; and 14Department of Public Health, University of Gent, 9000 Gent, Belgium | ||||
| Eur Heart J. 2011 Sep;32(17):2143-52 |
||||
| , Article | ||||
| , Austria, Belgium, France, Germany, Greece, Norway, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21471134 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2011 | English | , Observational study, Prospective study | |
| Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study. | ||||
| Guallar E, Banegas JR, Blasco-Colmenares E, Jiménez FJ, Dallongeville J, Halcox JP, Borghi C, Massó-González EL, Tafalla M, Perk J, De Backer G, Steg PG, RodrÃguez-Artalejo F. | ||||
| BMC Public Health. 2011 Sep 18;11:704. doi: 10.1186/1471-2458-11-704. |
||||
| , Article | ||||
| , Austria, Belgium, France, Germany, Greece, Norway, Russian Federation, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21923932 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2011 | English | , Observational study, Prospective study | |
| Continuous subcutaneous insulin infusions versus multiple daily injection of insulin in patients with type 1 diabetes: a long-term health economic analysis in the Norwegian and Swedish settings | ||||
| Goodall G1, Nicklasson L2, Zakrzewska K3, Foos V1,Valentine WJ1,Roze S1, Palmer AJ1 | ||||
| CORE—Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, 2 Medtronic AB, Järfälla, Sweden, 3 Medtronic AG, Tolochenaz, Switzerland | ||||
| Value in Health, 2006:9 (6) A227 |
||||
| , Poster | ||||
| , Norway, Sweden | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Economic evaluation | |